FDA REVOKES EUA FOR BAMLANIVIMAB FOR COVID-19
April 16, 2021
In November of 2020, the FDA issued an emergency use authorization (EUA) for bamlanivimab, an investigational monoclonal antibody designed to block the coronavirus’ attachment and entry into human cells, for the treatment of mild-to-moderate COVID-19. However, in April of 2021, the FDA revoked that EUA. Based on ongoing analysis of emerging scientific data, viral variants of COVID-19 were found to be resistant to bamlanivimab, and with no testing technologies available to allow healthcare providers to test individual patients for COVID-19 variants, the potential benefits of using the drug no longer outweighed the risks.
